前列腺立体定向放疗是否使用水凝胶直肠间隔物:EPIC 生活质量分析
该前瞻性单中心注册研究分析 2012–2023 年前列腺 SBRT 患者,比较使用水凝胶直肠间隔物(RS,n=290)与未使用(n=1815)的生活质量趋势。结果显示 SBRT 后 EPIC 评分下降轻微、约 6 个月恢复基线并稳定至 5 年,RS 未带来持久且有临床意义的生活质量改善,仅 2 个月时点在部分领域出现短暂优势。
要点
- 前列腺 SBRT 后生活质量下降轻微且多为暂时性,约 6 个月恢复基线。
- 水凝胶直肠间隔物未带来持久且有临床意义的生活质量改善。
- 仅放疗后 2 个月时点,间隔物组在泌尿刺激、肠道和活力领域有短暂优势。
核心结论
- 前列腺 SBRT 后生活质量下降轻微且大多在约 6 个月内恢复,水凝胶直肠间隔物未带来持久且有临床意义的生活质量改善。
研究设计与样本
- 前瞻性单中心注册研究,分析 2012 至 2023 年前列腺 SBRT 患者,使用直肠间隔物 290 例、未使用 1815 例。
- 采用 EPIC-26 在基线和放疗后至 5 年收集生活质量评分,主要终点为线性混合效应模型评估的生活质量随时间趋势。
- 治疗使用 CT 与 MRI 融合、3 至 6 枚基准标记实时追踪的机器人 SBRT,临床靶区包括前列腺加近端精囊,计划靶区边缘除后方 3 mm 外为 5 mm,5 次给予 35–36.25 Gy。
主要发现
- 两组年龄、前列腺特异性抗原和前列腺体积无差异;间隔物组更多为近期治疗、中高危疾病(96% 对 85%)、使用雄激素剥夺治疗(52% 对 39%)和白种人(63% 对 55%),p 均 < .001。
- 基线 EPIC 评分相似,SBRT 后 EPIC 评分下降轻微,约 6 个月接近基线并稳定至 5 年。
- 按间隔物与否比较,生活质量随时间趋势无临床显著差异;仅放疗后 2 个月时点,间隔物组在泌尿刺激、肠道和活力领域达到 1 倍和/或 2 倍最小重要差异阈值,生活质量更有利。
- 即使在基线性功能 EPIC ≥60 且未使用雄激素剥夺治疗的亚组中,间隔物组之间也无持久临床显著生活质量差异。
关键数值与推荐
- 临床重要变化分析采用既定最小重要差异阈值,比较各时点两组中有意义生活质量下降的患者比例。
- 放疗后 2 个月时点,间隔物组在泌尿刺激、肠道和活力领域达到 1 倍和/或 2 倍最小重要差异阈值。
临床怎么用
- 前列腺 SBRT 后生活质量下降多为短暂,咨询时可告知患者约 6 个月恢复。
- 水凝胶直肠间隔物不应常规期望带来持久生活质量获益,决策需结合其他因素。
局限性
- 为单中心前瞻性注册研究,非随机分组,间隔物组与未使用组在疾病风险、雄激素剥夺治疗使用和种族构成上存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: After prostate radiation therapy (RT), bowel, urinary, and sexual side effects and quality of life (QOL) declines are common. Phase 3 trials of rectal spacers (RSs) using ≥20 fractions found clinical and dose benefits and reduced QOL declines. However, the role of RS in stereotactic body radiation therapy (SBRT) is undefined. METHODS AND MATERIALS: A prospective single-institution registry of prostate SBRT from 2012 to 2023 was analyzed by RS use (n = 290) versus no-RS (n = 1815). QOL scores were collected via Expanded Prostate Cancer Index Composite-26 at baseline and up to 5 years post-RT. Treatment used computed tomography and magnetic resonance imaging fusion and 3 to 6 fiducials for real-time tracking with Robotic SBRT (CyberKnife, Accuray Inc). Clinical target volume included prostate plus proximal seminal vesicles. Planning target volume margins were 5 mm except 3 mm posteriorly (35-36.25 Gy was delivered in 5 fractions). The primary endpoint was QOL trend over time by RS versus no-RS as evaluated by linear mixed-effects models that accounted for within-subject variability by controlling for key clinical and demographic characteristics. Clinically important change analyses were conducted using established minimally important difference (MID) thresholds to compare proportion of patients in each group with meaningful QOL declines at each timepoint. RESULTS: There were no differences in age, prostate specific antigen, or prostate volume between groups. RS was associated with more recent treatment (p < .001), intermediate- and high-risk disease (96% vs 85%; p < .001), androgen deprivation therapy use (52% vs 39%; p < .001), and Caucasian patients (63% vs 55%; p < .001). Baseline EPIC scores were similar. Declines in EPIC scores post-SBRT were small, approaching baseline after 6 months and remaining stable to 5 years. There were no clinically significant differences in QOL trend over time by RS vs no-RS. For the 2-month post-RT timepoint alone, the RS group had more favorable QOL with 1×MID and/or 2×MID thresholds met for urinary irritation, bowel, and vitality domains. No durable clinically significant QOL differences occurred between RS groups even in the baseline sexual domain EPIC ≥60/no androgen deprivation therapy subgroup. CONCLUSIONS: SBRT produced only modest, largely transient QOL declines that resolved by ∼6 months. RS did not confer a durable clinically meaningful QOL improvement; an isolated 2×MID signal at 2 months favored RS in select domains, but this was transient, and nondurable.
引用
- Flanagan MM, Almekdash MH, Collins SP, et al. To Space or Not to Space: The EPIC Question for Prostate Stereotactic Radiation Therapy With or Without Hydrogel Rectal Spacer. Pract Radiat Oncol. 2025. PMID: 41386586. doi:10.1016/j.prro.2025.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。